U.S. Personal Products Stock News

In February 2026, Howmet Aerospace completed several fixed‑rate senior unsecured note offerings totaling about US$1.20 billion, with maturities ranging from 2028 to 2036, to help finance its approximately US$1.80 billion proposed acquisition of Consolidated Aerospace Manufacturing and supplement borrowings under its commercial paper program and existing cash. This combination of debt‑funded acquisition plans, ongoing share repurchases, and solid 2025 earnings puts Howmet’s balance sheet,...

Dollar General (NYSE:DG) has launched a new Dollar General Market format featuring an expanded grocery assortment. The remodel brings more fresh produce, meat, and everyday food essentials to communities with limited grocery options. The change reflects the company’s focus on community investment and access to food in underserved areas. For you as an investor, this move sits at the intersection of discount retail and everyday essentials, an area where consistent foot traffic can matter as...

Why Goodyear’s latest earnings matter for shareholders Goodyear Tire & Rubber (GT) just reported fourth quarter and full year 2025 results, with stronger quarterly profit but a full year net loss, giving investors mixed signals on the stock’s recent performance. See our latest analysis for Goodyear Tire & Rubber. The mixed earnings story is also showing up in the trading data, with the 90 day share price return of 9.83% pointing to improving momentum. In contrast, the 1 year total shareholder...

Verra Mobility (VRRM) drew fresh investor attention after securing a 10 year contract worth roughly US$160 million with Hawaii’s Department of Transportation to expand its automated red light and speed enforcement program statewide. See our latest analysis for Verra Mobility. The Hawaii contract follows another large win with New York City earlier in February. Together, these updates contrast with a softer share price picture, with a 30-day share price return of an 11.16% decline, a...

If you are wondering whether DocuSign's current share price reflects its true worth, you are not alone. This article will help you frame that question clearly. With the stock closing at US$44.48 and returns of a 0.8% decline over 7 days, a 22.6% decline over 30 days, a 31.4% decline year to date and a 47.0% decline over 1 year, many investors are reassessing what a fair price looks like for DocuSign. Recent coverage has focused on how DocuSign is repositioning itself within the broader...

Paychex Director Joseph Doody recently acquired additional shares of NasdaqGS:PAYX, signaling increased personal exposure to the company. The insider purchase comes as Paychex shares trade at $91.24 following a 16.0% decline year to date. This transaction adds a fresh data point for investors watching insider activity at Paychex. For investors tracking Paychex, the timing of this insider buying stands out against a weaker recent share performance. The stock is at $91.24, with a 7 day return...

Vestis (VSTS) moved after releasing first quarter 2026 results, which showed lower sales and a net loss. The company also reaffirmed its full year guidance for revenue, projecting results between flat and a 2% decline. See our latest analysis for Vestis. The earnings release and reaffirmed guidance seem to have shifted sentiment in the short term, with a 1-day share price return of 3.91% and a 30-day share price return of 16.50% at a latest share price of $7.98. However, the 1-year total...

Earlier in February 2026, Albemarle said it had idled the last operating train at its Kemerton lithium hydroxide plant in Western Australia, recorded US$245.60 million of long‑lived asset impairments for the December 2025 quarter, and reported a quarterly net loss despite higher sales. At the same time, Albemarle guided to 2026 net sales of US$5.70 billion to US$6.00 billion with flat volumes, while shifting Kemerton into care and maintenance but planning to meet lithium hydroxide demand...

Voya Financial (VOYA) has launched a new fixed income offering of senior, unsecured fixed rate notes, shortly after filing an omnibus shelf registration that covers debt, equity, preferred stock, depositary shares, warrants, and units. See our latest analysis for Voya Financial. Voya’s new notes come after a period where momentum has softened slightly in the short term, with a 30 day share price return of a 1.83% decline. The 1 year total shareholder return of 6.56% and 5 year total...

If you are wondering whether Regeneron Pharmaceuticals is still priced fairly after a strong multi year run, or if the market is missing something in plain sight, this article will help you weigh what you are really paying for. The stock most recently closed at US$779.67, with returns of 3.5% over 30 days and 74.2% over 5 years, so recent moves and longer term performance give mixed signals on how the market is pricing its potential and risks. Recent headlines around Regeneron have focused...

Liberty Global Ltd. has reported its full-year 2025 results, with sales rising to US$4,878.5 million from US$4,341.9 million, but swinging from a net income of US$1.59 billion to a very large net loss of US$7.14 billion and a basic loss per share from continuing operations of US$20.86. The combination of higher revenue and a very large reported loss raises questions about cost structure, one-off charges, and how resilient the business model really is. We’ll now consider how this sharp move...

Insmed (INSM) has been in focus after its fourth quarter and full year 2025 earnings, where strong revenue from ARIKAYCE and new drug BRINSUPRI contrasted with a wider net loss and ambitious 2026 sales guidance. See our latest analysis for Insmed. Insmed’s recent earnings and guidance have come alongside a sharp move in the share price, with a 10.86% 7 day share price return and 5.57% 30 day share price return partly offsetting a 21.10% 90 day share price decline. The 1 year total shareholder...

If you are wondering whether CONMED's current share price reflects its true worth, this article walks through the key signals that matter for value focused investors. The stock last closed at US$45.14, with a recent return of 8.0% over 7 days and 8.4% over 30 days, set against an 11.4% return year to date and a 25.4% decline over the past year. These moves sit against a backdrop of ongoing interest in medical devices and surgical technologies. Investors are watching how companies like CONMED...

If you are wondering whether Corcept Therapeutics at around US$34.82 is starting to look interesting on price, you are not alone. The stock has been drawing attention from investors focused on value. The share price has seen a 12.9% decline over the last 7 days, 20.8% over 30 days, 8.8% year to date and 45.2% over 1 year, even though the 3 year and 5 year returns sit at 63.4% and 38.4% respectively. Recent coverage has largely centered on ongoing developments in its pharmaceutical and...

Blackstone (NYSE:BX) has agreed to acquire Champions Group, a multi-service home services platform. Blackstone Infrastructure has received Federal Energy Regulatory Commission approval for its planned acquisition of TXNM Energy. Both moves expand Blackstone’s presence in essential services and energy infrastructure businesses. For you as an investor, these updates highlight how Blackstone is putting capital to work in areas tied to everyday needs, from home services to energy transmission...

Earlier this week, Markel Group’s insurance operations announced a collaboration with cyber risk specialist Upfort to offer eligible U.S. cyber policyholders access to Upfort Shield, an AI‑powered, multi‑layer defense platform and endpoint detection tools aimed at helping reduce cyberattack risks. This move deepens Markel’s service offering in cyber insurance by pairing coverage with embedded risk‑prevention technology for middle‑market businesses, potentially strengthening customer...

Akamai Technologies recently reported fourth-quarter 2025 results showing revenue of US$1,094.91 million and full-year 2025 revenue of US$4,208.18 million, alongside lower net income and earnings per share compared with the prior year. At the same time, the company issued 2026 guidance calling for higher capital spending and projecting revenue of US$1,060 million to US$1,085 million for the first quarter and US$4.40 billion to US$4.55 billion for the full year, as it invests heavily in its...

Earlier in February 2026, Goldman Sachs initiated coverage of Samsara Inc., praising its Connected Operations Cloud, while G2 ranked Samsara the No. 1 Supply Chain & Logistics Software Product of 2026 based on over 2,100 verified customer reviews. Together, the analyst endorsement and customer-driven award spotlight Samsara’s role in digitizing physical operations by pairing edge hardware with an AI-powered cloud platform. We’ll now examine how Goldman Sachs’ positive coverage and Samsara’s...

If you are looking at Cleveland-Cliffs and wondering whether the recent share price really reflects the value of the business, this article will walk through what the numbers are saying. The stock last closed at US$10.65, with returns of 2.6% over 7 days, a 29.4% decline over 30 days, and year to date and 1 year returns of 21.7% and 6.2% declines respectively, while the 3 year and 5 year returns are 46.0% and 20.2% declines. These moves sit against a broader backdrop of ongoing interest in...

For readers wondering whether Keysight Technologies at around US$243 per share still offers value or if the easy money is already gone, this article will walk through what the current price might be implying. The stock has returned 4.3% over the last 7 days, 14.4% over the past month, 17.9% year to date and 38.8% over the past year, with longer term returns of 54.3% over 3 years and 72.1% over 5 years. Recent coverage has focused on Keysight's role in electronic design and test solutions, as...

XPeng (NYSE:XPEV) has launched a unified global in-app charging payment solution through a new partnership with Antom. The rollout begins outside mainland China with coverage in Hong Kong and planned expansion into Southeast Asia. The service enables cross-border, multi-currency payments for electric vehicle charging within XPeng's ecosystem. XPeng, an electric vehicle maker listed on the NYSE under ticker XPEV, is expanding its charging and software ecosystem as global EV adoption scales...

Natera recently attracted positive attention after Duquesne Family Office highlighted the company’s strong oncology testing momentum, including 54% growth in third-quarter oncology volumes and expanding use of its Signatera molecular residual disease blood test, which now represents nearly a quarter of total tests. While Natera remains unprofitable, its recurring revenue base, cash generation and scalable diagnostics platform across women’s health, oncology and organ health are drawing...

If you are wondering whether Doximity is starting to look like value or is still priced for high expectations, you are in the right place to assess what the current share price really reflects. The stock most recently closed at US$25.55, after a 2.1% move over the past week, but with much steeper returns of a 37.1% decline over 30 days, a 41.0% decline year to date, and a 64.7% decline over the past year. These sharp price moves have come alongside ongoing discussion about Doximity's role as...

If you are wondering whether Scholar Rock Holding's recent share price puts it on sale or already prices in a lot of optimism, you are asking the right question for a valuation focused look at the stock. The shares recently closed at US$48.00, with returns of 4.4% over 7 days, 8.4% over 30 days, 12.1% year to date, 27.3% over 1 year, a very large gain over 3 years, and a 11.3% decline over 5 years. This naturally raises questions about how much upside or risk is now built into the...